10-Q · May 13, 2026
Veru's 10-Q for the quarter ending March 31, 2026, shows a reduction in operating losses due to reduced expenses, yet it remains without revenue, continuing a trend of negative earnings. The company reported net losses,…
Earnings analysis · 10-Q
VERU earnings analysis
Filed August 10, 2026 · Our reading of the company's report
The latest report
Veru reported a third-quarter diluted loss of $0.30 per share, beating the $0.32 consensus estimate, and reduced net loss to $6,988,350 from $7,332,820 year over year. Cash increased to $23,880,142 after a $23,366,345…
Read full summary
Veru reported a third-quarter diluted loss of $0.30 per share, beating the $0.32 consensus estimate, and reduced net loss to $6,988,350 from $7,332,820 year over year. Cash increased to $23,880,142 after a $23,366,345 equity financing, while operating expenses and nine-month operating cash burn declined. However, the filing includes an explicit going-concern conclusion, with $20,551,655 of nine-month operating cash outflow and management stating that current cash is insufficient for the subsequent 12 months; the new baby-shelf limitation further raises financing risk.
Gross and operating margin
How much of each revenue dollar the business keeps.
One point per quarterly or annual filing. Both margins are shares of that report's revenue.
How we read each report
Our analysis across the last few reports.
Our model's reading of each filing, not the share price or the market's reaction. Annual and quarterly reports each occupy one position.
Reported figures
- Earnings per share
- $-0.3
- Segment
- Single drug-development operating segment: no product revenue from continuing operations; three-month R&D expense was $4,352,668 and G&A expense was $3,361,013, producing a net loss of $6,988,350.
What stood out
-
EPS beat and net loss narrowed
Third-quarter diluted EPS was a $0.30 loss versus a $0.50 loss in the prior-year quarter and the $0.32 consensus estimate, while net loss narrowed to $6,988,350 from $7,332,820.
-
PLATEAU enrollment completed
PLATEAU enrollment was completed in approximately 200 patients, and the study’s interim analysis is planned for calendar Q1 2027 after all patients have received 32 weeks of treatment.
-
Cash balance increased year to date
Cash, cash equivalents and restricted cash increased to $23,880,142 at June 30, 2026 from $15,794,562 at September 30, 2025, supported in part by $23,366,345 of net proceeds from an underwritten equity offering.
-
Operating expense base contracted
Nine-month operating expenses declined to $20,356,664 from $28,071,569, with R&D decreasing to $8,842,633 from $12,669,495 and G&A decreasing to $11,514,031 from $15,402,074.
-
Lower operating cash burn
Nine-month operating cash outflow improved to $20,551,655 from $24,551,752, while capital expenditures were only $0, indicating minimal capex intensity.
-
No-cost Wegovy supply secured
Novo Nordisk agreed to supply Wegovy at no charge for the PLATEAU study, and the filing states that the drug supply cost has a net-zero effect on R&D expense because the product has no alternative future use.
What to watch
-
Going-concern uncertainty
Management concluded that substantial doubt exists about the Company’s ability to continue as a going concern for at least 12 months after issuance, stating that cash and cash equivalents are insufficient for the next 12 months of operating, investing and financing needs.
-
Continued financing requirement
The Company had $20,551,655 of operating cash outflow during the first nine months and expects to rely on equity offerings, debt financing or other capital sources; the filing states additional capital may not be available when needed.
-
Baby-shelf rule constrains capital access
A new risk factor states that the SEC baby-shelf rule limits primary shelf offerings to one-third of public float when public float is below $75 million; Veru reported public float of approximately $65.5 million and an available ATM offering of up to $21.8 million as of July 2, 2026.
-
Uncertain ONCO warrant liquidity
The Company’s remaining ONCO Warrant was valued at $1,911,386 at June 30, 2026, but the filing states there is no assurance as to whether or when cash proceeds may be received from exercising the warrant.
-
Clinical supply termination risk
Novo Nordisk may terminate the clinical supply agreement for convenience upon 60 days’ prior notice, creating a potential supply disruption for the PLATEAU study despite Wegovy being supplied at no charge.
-
Payables and cash-burn pressure
The Company reported $1,709,689 of accounts payable and $949,092 of accrued expenses and other current liabilities at June 30, 2026, while operating cash flow was negative $20,551,655 for the nine-month period.
Management's outlook
No numeric revenue or EPS guidance was provided. Management stated that the Phase 2b PLATEAU interim analysis is planned for the first quarter of calendar 2027 after 32 weeks of treatment, with the primary endpoint assessed at 68 weeks. The Company also stated that cash and cash equivalents as of the financial statement issuance date are insufficient to fund operating, investing and financing needs for the subsequent 12 months.
Earlier filings 4
10-Q · February 11, 2026
Veru reported no net revenue for the quarter ended December 31, 2025, a continuing operating loss of $5,424,015 and a net loss per share of $0.26. Cash increased to $32,991,417 at December 31, 2025 following a public…
10-Q · May 8, 2025
Veru reported no net revenues for the quarter ended March 31, 2025 and a GAAP net loss of $7,901,619 (loss per share $0.05), an improvement versus the prior-year quarter net loss of $10,025,948 (loss per share $0.07).…
10-Q · May 8, 2024
Veru reported Q2 (three months ended March 31, 2024) revenue of $4.14M, down from $6.59M a year earlier, with gross profit collapsing to $678k (16.4% margin) vs $4.09M (62.1%) in prior year. The company improved…
This is our reading of a public filing, not the filing itself. Analysis can contain errors; check the source document for full context.